Research progress on activation transcription factor 3: A promising cardioprotective molecule.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 31 03 2023
revised: 05 06 2023
accepted: 15 06 2023
medline: 24 7 2023
pubmed: 25 6 2023
entrez: 24 6 2023
Statut: ppublish

Résumé

Activation transcription factor 3 (ATF3), a member of the ATF/cyclic adenosine monophosphate response element binding family, can be induced by a variety of stresses. Numerous studies have indicated that ATF3 plays multiple roles in the development and progression of cardiovascular diseases, including atherosclerosis, hypertrophy, fibrosis, myocardial ischemia-reperfusion, cardiomyopathy, and other cardiac dysfunctions. In past decades, ATF3 has been demonstrated to be detrimental to some cardiac diseases. Current studies have indicated that ATF3 can function as a cardioprotective molecule in antioxidative stress, lipid metabolic metabolism, energy metabolic regulation, and cell death modulation. To unveil the potential therapeutic role of ATF3 in cardiovascular diseases, we organized this review to explore the protective effects and mechanisms of ATF3 on cardiac dysfunction, which might provide rational evidence for the prevention and cure of cardiovascular diseases.

Identifiants

pubmed: 37355225
pii: S0024-3205(23)00504-0
doi: 10.1016/j.lfs.2023.121869
pii:
doi:

Substances chimiques

Transcription Factor 3 0
Activating Transcription Factor 3 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

121869

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None declared.

Auteurs

Haoteng Ke (H)

The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China; Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Zexing Chen (Z)

The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China; Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Xuanbin Zhao (X)

The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China; Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Chaobo Yang (C)

Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Tao Luo (T)

Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.

Wen Ou (W)

Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Lizi Wang (L)

Department of Health Management, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

Haiqiong Liu (H)

Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; Department of Health Management, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. Electronic address: lhq1027@smu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH